Cidara Therapeutics reacquires global development and commercial rights to CD 388
Cidara Therapeutics, Inc. a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced that it has entered into a definitive agreement with Johnson & Johnsonto reacquire the exclusive global development and commercial rights to CD 388, which is in development for the prevention of all strains of influenza A and B
CD 388 is a long-acting antiviral investigational drug invented and developed by Cidara that became the subject of an exclusive worldwide license and collaboration agreement established with Johnson & Johnson in April 2021.
All responsibility for future development, manufacturing, and commercialization activities of CD 388 will be assumed by Cidara. In exchange for reacquiring the exclusive global development and commercial rights to CD 388, Johnson & Johnson has received from Cidara a one-time upfront payment of $85 million and is eligible to receive potential additional development, regulatory, and commercial milestone payments.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins